The PRIMARY2 clinical trial demonstrated that PSMA PET/CT imaging can markedly lower the number of invasive prostate biopsies in men with suspected cancer after inconclusive or reassuring MRI, the investigators reported at the European Association of Urology meeting. The study showed high negative predictive value in selected populations and supports integrating molecular imaging into diagnostic algorithms. Clinical adoption could shrink diagnostic pathways, reduce procedure‑related harms, and alter tissue‑sampling strategies in urology. Payors and guideline committees will weigh cost, access to PET imaging and comparative performance versus MRI‑directed biopsy prior to broad reimbursement and practice change.